FDA GLP-1 Telehealth Warning Letters: What They Said in 2026

Between September 2025 and mid-2026 the FDA sent several rounds of warning letters to telehealth companies selling compounded semaglutide and tirzepatide, including 30 letters announced on March 3, 2026. The letters said the companies' websites made false or misleading claims, mainly that compounded drugs were the same as FDA-approved Wegovy, Ozempic or Zepbound, or that the telehealth brand itself made the drug.

That's the news. The useful part for you is that the letters quote the exact marketing lines the FDA objected to, which makes them a ready-made decoder for any GLP-1 sales page you land on.

A quick timeline of FDA's GLP-1 telehealth actions

Date	What happened
Sep 9, 2025	FDA announced a broad crackdown on deceptive drug advertising: "thousands" of letters and about 100 cease-and-desist letters. Warning letters dated the same day went to telehealth firms selling compounded GLP-1s, including two to Hims & Hers.
Feb 6, 2026	FDA said it intends to restrict GLP-1 active ingredients meant for unapproved compounded drugs that are mass-marketed as alternatives to approved ones, naming Hims & Hers among others. It repeated that marketing can't call compounded products generic or the same as approved drugs.
Feb 20, 2026	Date on a batch of warning letters to telehealth companies (for example Belle, MEDVi, Join Josie, Strut).
Mar 3, 2026	FDA announced 30 warning letters to telehealth companies over compounded GLP-1 marketing, calling it the second group sent to telehealth firms.
Jun 8, 2026	More letters, including to Altru Telehealth, Ready Med and Momentum Health 360.
Jun 15, 2026	FDA posted a page for telehealth companies listing common compliance pitfalls when promoting compounded drugs.

Warning letters keep appearing, so this table is a snapshot as of late October 2026. You can always search "telehealth" in FDA's public warning letter database for the latest.

What did the letters actually object to?

The letters come from FDA's Office of Compounding Quality and Compliance. They read a bit like a red-pen edit of a marketing page. Here are real phrases FDA quoted:

• Hims (Sep 2025): "Same active ingredient as Ozempic and Wegovy" and "Clinically proven ingredients." FDA said these suggested the compounded semaglutide was the same as approved drugs, which it isn't.
• Altru Telehealth (Jun 2026): "Compounded semaglutide combines the FDA approved active ingredient semaglutide with a body safe vitamin such as B12," plus a claim that it "offers the same results but at a fraction of the cost of brand names," and that its "compounding pharmacies are all FDA approved."
• Belle (Feb 2026): product images with the company's own name on the label. FDA said that implied Belle was the compounder, which it was not.

The legal hook in most of these letters is misbranding: section 502(a) of the Food, Drug, and Cosmetic Act (labeling that is false or misleading) and section 502(bb) (false or misleading advertising of compounded drugs). Companies were given 15 working days to respond and fix the problems, and warned that failing to do so could lead to seizure or an injunction.

One important nuance: a warning letter is FDA telling a company what it considers violations and giving it a chance to correct them. It is not a court ruling, and many companies update their websites afterward. The lesson is about the claims, not a permanent verdict on any one brand.

The five claims FDA says to avoid

FDA's June 2026 page for telehealth companies boils the problem down to five pitfalls, each with a made-up example. Turned around, it's a checklist for shoppers:

What FDA says is a problem	FDA's example phrase	Why it matters to you
Branding that implies the telehealth company is the compounder	"Our in-house pharmacy crafts every dose"	You may not know who actually made your medicine
Calling a compounded drug generic or the same as an approved drug	"Our compounded semaglutide is just like Wegovy"	Generics are FDA-approved; compounded drugs are not
Implying FDA approval or review	"This FDA-reviewed formula is proven safe"	FDA doesn't review compounded drugs for safety, effectiveness or quality before sale
Claiming clinical equivalence	"Clinically shown to deliver the same results as the brand-name drug"	The big trials were done on the approved products, not on compounded versions
Claiming FDA-approved sourcing	an "FDA-approved" or "FDA-licensed" pharmacy	FDA says it does not approve or license any facility

That last one surprises people. Pharmacies are licensed by state boards; outsourcing facilities register with FDA, but FDA's letters say registration is not "approval" or "licensure." So "FDA-approved pharmacy" is a phrase that should make you squint.

Why does FDA care so much about wording?

Because the wording is doing the safety work in a shopper's head. If you believe a product is "the same as Wegovy," you assume the Wegovy trials, label and manufacturing controls apply to it. They don't.

FDA's consumer page on unapproved GLP-1s gives some context. As of May 31, 2026, the agency had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, and it says those numbers are likely undercounts. It has also flagged dosing errors with compounded injectables, and says some compounders use salt forms such as semaglutide sodium or acetate that are different active ingredients from the approved drugs. An adverse event report doesn't prove the drug caused the problem (our guide on adverse event reports explains why), but it shows why regulators want marketing to be precise.

What shoppers can take from the letters

You don't need to become a regulatory lawyer. Three habits cover most of it:

1. Translate the adjectives. "Same," "generic," "clinically proven," "FDA-approved pharmacy." If one of these is attached to a compounded product, mentally replace it with "not FDA-approved" and see if you still want to pay.
2. Find the real maker. If the vial or pen shows the telehealth brand, ask which pharmacy or outsourcing facility actually compounded it. FDA asked the companies the same question.
3. Look up the company. Search the business name in FDA's warning letter database. A past letter isn't proof of current wrongdoing, but you'll know what to ask about.

For the rest of the shopping process, use our telehealth appointment checklist for questions about screening, follow-up and price, and our online pharmacy verification guide to confirm the pharmacy is licensed in your state. If you're already on a compounded product, our compounded GLP-1 red flags guide covers what to raise with your prescriber.

Whatever you end up taking, write down the exact product name, strength and pharmacy each time you refill, whether in a notebook or a shot log like GLPily's. If something changes between fills, that record is the first thing your prescriber or pharmacist will ask for.

Common questions

How many warning letters has FDA sent to GLP-1 telehealth companies?

FDA's March 3, 2026 announcement covered 30 letters and called them the second group sent to telehealth firms; more letters followed in June 2026. FDA hasn't published a single running total for telehealth GLP-1 letters, so check its warning letter database for the current list.

Does a warning letter mean compounded GLP-1s are illegal?

No. Compounding is legal when pharmacies and outsourcing facilities meet the conditions in sections 503A or 503B of the law. These letters targeted false or misleading marketing claims, not compounding itself. FDA has separately said it intends to restrict GLP-1 ingredients used for mass-marketed compounded alternatives.

Is compounded semaglutide a generic version of Wegovy?

No. FDA says compounded drugs are not the same as FDA-approved generics, which go through FDA review before they're sold. Calling a compounded product "generic Wegovy" is one of the claims FDA has flagged.

Where can I report a misleading GLP-1 ad?

You can report illegal online medicine sales through FDA's BeSafeRx page, and side effects through FDA MedWatch. For urgent symptoms, call 911.